Related Experiment Video
Updated: Feb 12, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Podoplanin: An emerging cancer biomarker and therapeutic target
Harini Krishnan1, Julie Rayes2, Tomoyuki Miyashita3,4
1Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY, USA.
Abstract:
Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Emerging Adulthood
Introduction Cardiac Emergencies
Therapeutic Index
Applications of GIS: Disaster Management and Emergency Response
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...

